302 related articles for article (PubMed ID: 33208816)
1. First-line axitinib therapy is less effective in metastatic renal cell carcinoma with spindle histology.
Numakura K; Kobayashi M; Muto Y; Sekine Y; Takahashi M; Kashima S; Yamamoto R; Koizumi A; Nara T; Saito M; Narita S; Nanjyo H; Habuchi T
Sci Rep; 2020 Nov; 10(1):20089. PubMed ID: 33208816
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I; Borisov P; Abdelgafur A; Leonenkov R; Novikova O; Guseva I; Demchenkova M; Mikhailova N; Semenov A; Yurmazov Z; Sivunova I; Ramazanova M; Gamayunov S; Kosov D; Bratslavsky G
Target Oncol; 2019 Feb; 14(1):33-38. PubMed ID: 30607698
[TBL] [Abstract][Full Text] [Related]
3. Validation of the IMDC Prognostic Model in Patients With Metastatic Renal-Cell Carcinoma Treated With First-Line Axitinib: A Multicenter Retrospective Study.
Konishi S; Hatakeyama S; Numakura K; Narita S; Inoue T; Saito M; Tokui N; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Narita S; Kawaguchi T; Habuchi T; Ohyama C
Clin Genitourin Cancer; 2019 Oct; 17(5):e1080-e1089. PubMed ID: 31416753
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma.
Kameda T; Takayama T; Sugihara T; Takeshima S; Yamazaki M; Komatsubara M; Kamei J; Fujisaki A; Ando S; Kurokawa S; Fujimura T
Asia Pac J Clin Oncol; 2020 Aug; 16(4):241-246. PubMed ID: 32129940
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Axitinib After Nivolumab Failure in Metastatic Renal Cell Carcinoma.
Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Okumi M; Ishida H; Tanabe K
In Vivo; 2020; 34(3):1541-1546. PubMed ID: 32354960
[TBL] [Abstract][Full Text] [Related]
6. Baseline risk stratification or duration of prior therapy predicts prognosis in patients with metastatic renal cell carcinoma treated with axitinib.
Mizuno R; Mikami S; Takamatsu K; Shinojima T; Kikuchi E; Oya M
Jpn J Clin Oncol; 2017 Dec; 47(12):1170-1174. PubMed ID: 28977627
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
[TBL] [Abstract][Full Text] [Related]
8. Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study.
Johnson AC; Matias M; Boyle H; Escudier B; Molinier A; Laguerre B; Helissey C; Brachet PE; Dugué AE; Mourey L; Coquan E; Joly F
BMC Cancer; 2017 May; 17(1):355. PubMed ID: 28532444
[TBL] [Abstract][Full Text] [Related]
9. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre.
Matias M; Le Teuff G; Albiges L; Guida A; Brard C; Bacciarelo G; Loriot Y; Massard C; Lassau N; Fizazi K; Escudier B
Eur J Cancer; 2017 Jul; 79():185-192. PubMed ID: 28511146
[TBL] [Abstract][Full Text] [Related]
10. Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
Haanen JBAG; Larkin J; Choueiri TK; Albiges L; Rini BI; Atkins MB; Schmidinger M; Penkov K; Michelon E; Wang J; Mariani M; di Pietro A; Motzer RJ
ESMO Open; 2023 Jun; 8(3):101210. PubMed ID: 37104931
[TBL] [Abstract][Full Text] [Related]
11. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcomes of second-line treatment following prior targeted therapy in patients with metastatic renal cell carcinoma: a comparison of axitinib and nivolumab.
Suzuki K; Terakawa T; Furukawa J; Harada K; Hinata N; Nakano Y; Fujisawa M
Int J Clin Oncol; 2020 Sep; 25(9):1678-1686. PubMed ID: 32488547
[TBL] [Abstract][Full Text] [Related]
13. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DY
Eur J Cancer; 2016 Sep; 65():102-8. PubMed ID: 27487293
[TBL] [Abstract][Full Text] [Related]
14. Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: which is better?
Halit Aktepe O; Sinem Ardic F; Yuce D; Can Guven D; Guner G; Cagri Yildirim H; Kilickap S; Turker A; Kertmen N; Akin S; Aksoy S; Dizdar O; Yalcin S; Erman M
J BUON; 2021; 26(5):2067-2073. PubMed ID: 34761618
[TBL] [Abstract][Full Text] [Related]
15. Is Axitinib Still a Valid Option for mRCC in the Second-Line Setting? Prognostic Factor Analyses From the AXIS Trial.
Bracarda S; Bamias A; Casper J; Negrier S; Sella A; Staehler M; Tarazi J; Felici A; Rosbrook B; Jardinaud-Lopez M; Escudier B
Clin Genitourin Cancer; 2019 Jun; 17(3):e689-e703. PubMed ID: 31072748
[TBL] [Abstract][Full Text] [Related]
16. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.
Konishi S; Hatakeyama S; Tanaka T; Ikehata Y; Tanaka T; Fujita N; Ishibashi Y; Yamamoto H; Yoneyama T; Hashimoto Y; Yoshikawa K; Kawaguchi T; Masumori N; Kitamura H; Ohyama C
Med Oncol; 2018 Nov; 36(1):6. PubMed ID: 30474747
[TBL] [Abstract][Full Text] [Related]
17. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101.
Tomita Y; Motzer RJ; Choueiri TK; Rini BI; Miyake H; Oya M; Albiges L; Aizawa M; Umeyama Y; Wang J; di Pietro A; Schmidinger M
ESMO Open; 2023 Dec; 8(6):102034. PubMed ID: 37866029
[TBL] [Abstract][Full Text] [Related]
19. Prognostic outcomes in patients with metastatic renal cell carcinoma receiving second-line treatment with tyrosine kinase inhibitor following first-line immune-oncology combination therapy.
Matsushita Y; Kojima T; Osawa T; Sazuka T; Hatakeyama S; Goto K; Numakura K; Yamana K; Kandori S; Fujita K; Ueda K; Tanaka H; Tomida R; Kurahashi T; Bando Y; Nishiyama N; Kimura T; Yamashita S; Kitamura H; Miyake H;
Int J Urol; 2024 May; 31(5):526-533. PubMed ID: 38240169
[TBL] [Abstract][Full Text] [Related]
20. A Prospectivly Randomized Phase-II Trial of Axitinib versus Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma (BERAT Study).
Grünwald V; Hilser T; Meiler J; Goebell PJ; Ivanyi P; Strauss A; Hartmann A; Bedke J; Bergmann L
Oncol Res Treat; 2022; 45(5):272-280. PubMed ID: 35045416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
